



Ingrezza in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

NEUROLOGY · TARDIVE DYSKINESIA

The clinical situation

Ingrezza (valbenazine) is an FDA-approved oral selective VMAT2 inhibitor indicated for adults with tardive dyskinesia and for chorea associated with Huntington disease. Manufactured by Neurocrine Biosciences. Standard dosing initiates at 40 mg once daily, titrated to 80 mg after one week, with lower ranges in CYP2D6 poor metabolisers and concomitant strong inhibitors; ambient-storage oral capsule.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating neurologist or psychiatrist confirms AIMS-rated TD diagnosis or HD chorea and documents prior exposure history and response.
- 2 Treating centre confirmed.** A Saudi tertiary neurology/movement-disorder centre in Riyadh, Jeddah, or Dhahran accepts the case.
- 3 SFDA named-patient application.** Clinical rationale, patient reference, and product details are filed; SFDA NPP electronic submission.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; ambient-temperature shipment.
- 5 Arrival & administration.** Patient begins once-daily dosing with physician-guided titration; AIMS/chorea scoring reassessed at 4-8 weeks.

Indicative economics

Reference US cash-pay range: USD 9,500–11,000 per 30-day supply. SFDA documentation, logistics, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

7–14 days from a complete SFDA application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and SFDA review. **Logistics.** Ambient-temperature shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Ingrezza × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/ingrezza-saudi-arabia.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team